Protagonist Therapeutics Inc. (PTGX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XBER Summary
PTGX Chart
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to earnings of $3.26 per share a year ago.
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update
Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1st Conference call to be held June 2nd at 8AM EDT to discuss rusfertide data presented at ASCO Full dataset from Phase 3 ICONIC-LEAD trial with icotrokinra in patients with moderate-to-severe plaque psoriasis (PsO) presented at the 2025 AAD Meeting in March; data from adolescent subset presented at World Congress of Pediatric Dermatology in April Positive top line results from icotrokinra Phase 2b ANTHEM trial in moderately to severely active ulcerative colitis (UC) announced in March, data to be presented at medical conference later in 2025 Cash, cash equivalents and marketable securities of $697.9 million as of March 31, 2025, anticipated to provide cash runway through at least end of 2028 NEWARK, CALIFORNIA / ACCESS Newswire / May 6, 2025 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update. "Protagonist is off to a very strong 2025 with multiple transformational events in the first quarter for our two late-stage partnered assets, rusfertide and icotrokinra which are progressing to NDA filings by year end," said Dinesh V.
Protagonist Therapeutics Reports Granting of Inducement Award
NEWARK, CA / ACCESS Newswire / April 16, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the discovery and development of peptide-based therapeutics, today announced that on April 15, 2025 (the "Grant Date"), it issued an equity inducement award to a new employee upon his commencement of employment with the Company in accordance with the terms of his employment offer letter. The award was granted under the Company's Amended and Restated 2018 Inducement Plan, which was adopted on May 29, 2018, and amended on February 18, 2020 and February 15, 2022.
Protagonist Therapeutics Inc. Dividends
Protagonist Therapeutics Inc. Earnings
| 5 May 2025 Date | | 0.11 Cons. EPS | - EPS |
| 25 Feb 2025 Date | | 0.25 Cons. EPS | 1.98 EPS |
| 4 Nov 2024 Date | | - Cons. EPS | - EPS |
| 31 Oct 2024 Date | | - Cons. EPS | - EPS |
| 5 Aug 2024 Date | | - Cons. EPS | - EPS |
| 5 May 2025 Date | | 0.11 Cons. EPS | - EPS |
| 25 Feb 2025 Date | | 0.25 Cons. EPS | 1.98 EPS |
| 4 Nov 2024 Date | | - Cons. EPS | - EPS |
| 31 Oct 2024 Date | | - Cons. EPS | - EPS |
| 5 Aug 2024 Date | | - Cons. EPS | - EPS |
Protagonist Therapeutics Inc. (PTGX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Protagonist Therapeutics Inc. ever had a stock split?
Protagonist Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Dinesh V. Patel Ph.D. CEO | NASDAQ (NMS) Exchange | 74366E102 Cusip |
| US Country | 124 Employees | - Last Dividend | - Last Split | 11 Aug 2016 IPO Date |
Overview
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on the development of peptide-based drugs to address unmet medical needs in the areas of hematology and blood disorders, as well as inflammatory and immunomodulatory diseases. Incorporated in 2006, the company has dedicated its research and development efforts to create innovative treatments, leveraging its expertise in peptide technology. Headquartered in Newark, California, Protagonist Therapeutics stands at the forefront of drug development, working in collaboration with industry leaders such as Takeda and JNJ Innovative Medicines to bring new therapies to market.
Products and Services
List of key developmental drugs and collaborations:
- Rusfertide (PTG-300): An injectable hepcidin mimetic designed for the treatment of polycythemia vera and other blood disorders. Rusfertide has completed phase 2 clinical trials, showing promise as a novel therapeutic option. This development is part of a licensing and commercialization agreement with Takeda, aiming to make a significant impact on patients' lives by addressing the unmet needs in hematology.
- JNJ-2113: This orally delivered investigational drug is designed to block biological pathways involved in moderate-to-severe plaque psoriasis. Having completed phase 2b clinical trials, JNJ-2113 is developed in collaboration with JNJ Innovative Medicines. The partnership focuses on co-developing this Interleukin-23 receptor antagonist compound, which represents a novel approach to treating inflammatory diseases.
- PN-943: An orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, PN-943 has completed a phase 2 clinical trial for patients with moderate to severe ulcerative colitis. This drug aims to offer a targeted therapeutic approach, reducing the systemic side effects often associated with current treatments for this chronic and debilitating condition.
Contact Information
